ValuEngine lowered shares of Endo International (NASDAQ:ENDP) (TSE:ENL) from a buy rating to a hold rating in a research report released on Tuesday.

Several other analysts have also weighed in on the stock. TheStreet upgraded shares of Endo International from a d rating to a c- rating in a research note on Monday, August 20th. Morgan Stanley lifted their price objective on shares of Endo International from $7.00 to $17.00 and gave the company an equal weight rating in a research note on Friday, August 17th. Mizuho lifted their price objective on shares of Endo International to $17.00 and gave the company a neutral rating in a research note on Tuesday, August 14th. Canaccord Genuity reiterated a hold rating and issued a $13.00 price objective on shares of Endo International in a research note on Monday, August 13th. Finally, Royal Bank of Canada upgraded shares of Endo International from a sector perform rating to an outperform rating and set a $26.00 price objective for the company in a research note on Monday, August 13th. Two equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of Hold and a consensus target price of $13.60.

NASDAQ:ENDP opened at $16.01 on Tuesday. The firm has a market capitalization of $3.72 billion, a PE ratio of 4.17, a P/E/G ratio of 3.19 and a beta of 0.74. The company has a debt-to-equity ratio of -132.64, a current ratio of 1.07 and a quick ratio of 0.91. Endo International has a twelve month low of $5.27 and a twelve month high of $17.46.

Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Wednesday, August 8th. The company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.54 by $0.22. The company had revenue of $714.70 million during the quarter, compared to analyst estimates of $679.72 million. Endo International had a negative net margin of 34.72% and a positive return on equity of 237.45%. Endo International’s revenue for the quarter was down 18.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.93 EPS. analysts forecast that Endo International will post 2.6 EPS for the current fiscal year.

In related news, Director Roger H. Kimmel sold 26,074 shares of Endo International stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $15.90, for a total value of $414,576.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.80% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. Xact Kapitalforvaltning AB boosted its holdings in Endo International by 44.5% during the 1st quarter. Xact Kapitalforvaltning AB now owns 29,215 shares of the company’s stock worth $174,000 after acquiring an additional 9,000 shares during the last quarter. Neuburgh Advisers LLC boosted its holdings in Endo International by 84.2% during the 1st quarter. Neuburgh Advisers LLC now owns 36,234 shares of the company’s stock worth $215,000 after acquiring an additional 16,566 shares during the last quarter. Riverhead Capital Management LLC boosted its holdings in Endo International by 83.9% during the 1st quarter. Riverhead Capital Management LLC now owns 41,218 shares of the company’s stock worth $245,000 after acquiring an additional 18,800 shares during the last quarter. Tyers Asset Management LLC boosted its holdings in Endo International by 84.2% during the 1st quarter. Tyers Asset Management LLC now owns 46,116 shares of the company’s stock worth $274,000 after acquiring an additional 21,084 shares during the last quarter. Finally, Flinton Capital Management LLC boosted its holdings in Endo International by 84.2% during the 1st quarter. Flinton Capital Management LLC now owns 55,998 shares of the company’s stock worth $333,000 after acquiring an additional 25,602 shares during the last quarter. 98.43% of the stock is currently owned by hedge funds and other institutional investors.

Endo International Company Profile

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Read More: Leveraged Buyout (LBO)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.